Skip to content
Screener

Roivant Sciences ROIV Business Segments — Investment Income, Interest

Similar metrics at other companies

Indivior Pharmaceuticals, Inc. logo
INDVReportable Segment — Investment Income, Interest
$3M-25.0%
Zevra Therapeutics, Inc. logo
ZVRAReportable Segment — Investment Income, Interest
$1.48M-34.6%
Stitch Fix logo
SFIXReportable Segment — Investment Income, Interest
$2.12M-19.2%
Cadence Design Systems logo
CDNSReportable Segment — Investment Income, Interest
$9.94M-61.7%
NeoGenomics logo
NEOReportable Segment — Investment Income, Interest
$1.21M-46.4%
BOB
BOBSReportable segment — Investment Income, Interest
$1.62M+514%

Other financials

Income statement

See full
Revenue$1.4M-33.5%
Operating income-$366.0M-28.5%
Net income-$189.8M+15.0%
EPS (diluted)-$0.26+21.2%

Balance sheet

See full
Cash & equivalents$77.1M-18.7%
Total debt$107.2M+7.5%
Total equity$4.2B-2.6%
Total assets$5.3B+5.4%

Cash flow

See full
Operating cash flow-$270.5M-32.4%
CapEx$419.0K-89.6%
Free cash flow-$270.9M-30.0%

Valuation

See full
Market cap$25.37B+219%
Enterprise value$25.4B+219%
P/S3,368×+3,026×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp
FCF margin-10,901%-22,382pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0.0×
Current ratio16.7×-23.8×

Where this comes from

Reported directly by Roivant Sciences in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The source filing: Roivant Sciences’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:28 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q2 2026
Accession
0001635088-26-000090
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025
Other general and administrative expenses34,70632,830
Gain on litigation settlement(392)
Change in fair value of investments(36,637)19,125
Change in fair value of liability instruments2,329
Interest income(36,922)(48,322)
Other expense, net2,13011,208
Income tax (benefit) expense(3,958)4,649
Net loss$(290,606)$(273,911)

Item 1. Financial Statements (Unaudited).

FAQ

What is Roivant Sciences's business segments — investment income, interest?
Roivant Sciences (ROIV) reported business segments — investment income, interest of $36.92M in Q2 2026.
How has Roivant Sciences's business segments — investment income, interest changed year-over-year?
Roivant Sciences's business segments — investment income, interest decreased by 23.6% year-over-year, from $48.32M to $36.92M.
What is the long-term trend for Roivant Sciences's business segments — investment income, interest?
Over 2 years (2023 to 2025), Roivant Sciences's business segments — investment income, interest has grown at a 10.3% compound annual growth rate (CAGR), from $146.43M to $178.11M.
What does business segments — investment income, interest mean?
This is the interest income earned on cash, cash equivalents, and short-term investments held by the segment. It serves as a measure of the segment's ability to generate yield on its liquid assets.

Ask your AI about Roivant Sciences's business segments — investment income, interest.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude